Ligand validation:4TLX

FDA: DIHYDROFLAVINE-ADENINE DINUCLEOTIDE

FDA is a Ligand Of Interest in 4TLX designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4TLX_FDA_D_501	85%	18%	0.101	0.965	2.14	1.41	17	8	0	0	100%	1
4TLX_FDA_A_501	81%	18%	0.119	0.971	2.09	1.48	19	11	2	0	100%	1
4TLX_FDA_B_501	80%	19%	0.116	0.964	2.03	1.45	20	7	0	0	100%	1
4TLX_FDA_C_501	67%	11%	0.127	0.935	2.15	2.04	19	15	1	0	100%	1
4TM1_FDA_A_501	78%	16%	0.128	0.972	2.21	1.47	18	9	2	0	100%	1
4TM4_FDA_D_501	74%	19%	0.134	0.964	2.09	1.39	16	7	0	0	100%	1
3TSH_FDA_A_601	100%	38%	0.04	0.992	1.03	1.38	3	6	3	0	100%	1
7AA2_FDA_B_701	100%	55%	0.044	0.987	0.85	0.89	2	2	3	0	100%	1
6ZE6_FDA_A_701	100%	60%	0.044	0.984	0.72	0.8	-	1	3	0	100%	1
4U2S_FDA_A_605	99%	14%	0.064	0.997	1.76	2.08	9	9	5	0	100%	1
6ZE2_FDA_B_701	99%	60%	0.048	0.979	0.71	0.83	-	1	3	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.